UCI Women's Healthcare
Orange, California, 92868, United States
NCT Number: NCT00928499
Sacral Nerve Stimulation (SNS) delivers non-painful, mild electrical pulses to the sacral nerves to modulate the reflexes that influence the bladder, sphincter, and pelvic floor to improve or restore normal voiding function. Sacral nerve stimulation is indicated for refractory voiding dysfunction including urinary urgency/frequency, urinary urge incontinence, and nonobstructive urinary retention. Since its introduction, SNS has undergone significant improvements in design and application so that implantation is now a minimally invasive procedure under local and intravenous (IV) sedation. However, despite the progress made in advancing this therapy to a minimally invasive procedure, there are neither data nor guidelines on ideal program settings. The purpose of this study is to evaluate the programming parameter of cyclic versus continuous stimulation on efficacy of the therapy. If the therapy is equally efficacious at both settings, the cyclic setting has the advantage of resulting in a longer battery life.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Orange, California, 92868, United States
The components of SNS include a quadripolar lead wire that is placed adjacent to a sacral nerve root (typically S3), and an implantable pulse generator (IPG) that the lead wire is attached to. The IPG provides the electrical impulse and has several parameters that are amenable to adjustment including rate, strength and length of stimulation. Additionally, the stimulation can be programmed to be continuous or cyclic. If the therapy is equally efficacious at both settings, the cyclic setting has the advantage of resulting in a longer battery life. This would prolong the time interval between IPG replacements which would reduce the number of times a patient is exposed to a surgical procedure and may have a substantial impact on reducing cost to the healthcare system.
Participants will be randomized into one of two groups: either cyclic stimulation or continuous stimulation after IPG placement and will continue with this setting for four weeks. Subjects will return to the office 4 weeks post-op. They will complete a 3-day consecutive voiding diary just prior to their study visit. The subject will then undergo reprogramming to change the stimulation to the alternate pattern (from cyclic to continuous or vice versa as appropriate) keeping all other parameters the same. Subjects will be asked to return to the office 4 weeks after being switched to the alternate setting. She will complete a 3-day consecutive voiding diary just prior to the visit. The subject will also be asked their preference of mode of stimulation and the reason for their choice. After this visit, the participant will be switched to the mode of stimulation that is most efficacious for her.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
Other names: Sacral nerve stimulation
Time frame: After 4 weeks of stimulation a 3-day consecutive voiding diary was completed
Collected in the 3 day voiding diary depending on their primary diagnosis
Time frame: After 4 weeks of stimulation a 3-day consecutive voiding diary was completed
Collected in the 3 day voiding diary depending on their primary diagnosis
University of California, Irvine
Other
Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06198439
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Houston, Texas, United States
View Trial DetailsNCT05308979
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Orange, California, United States
View Trial DetailsNCT05882318
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Downey, California, United States
View Trial DetailsNCT03556891
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Downey, California, United States
View Trial Details